Dulaglutide
GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
Company n/r · Phase 4 · Completed · Enrollment 23
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Cyanocobalamin, then Dulaglutide | n/r | n/r | n/r | n/r |
| Dulaglutide, then Cyanocobalamin | n/r | n/r | n/r | n/r |
Not shown
- Cyanocobalamin, then Dulaglutide: endpoint not reported
- Dulaglutide, then Cyanocobalamin: endpoint not reported